Asia Pacific Antidepressants Drugs, Devices And Therapies Market Forecast 2018 & 2027

Asia Pacific Antidepressants Drugs, Devices And Therapies Market Forecast 2018 & 2027

KEY INSIGHTS

The Asia Pacific is currently ranked third in terms of revenue from the depression drugs and devices market, where the expected growth rate of the antidepressants drugs, devices, and therapies market is 3.32% CAGR during the forecasting years of 2019-2027.

MARKET INSIGHTS

China, India, Japan, South Korea, Australia and the remaining countries constituting the Rest of Asia Pacific segment are considered for the market study. The high cost of psychotherapy restraining people to take services, which is acting as a major hindering factor for market growth. Drug makers witness a downfall of almost xx% of their revenue as soon as they lose patent protection. With the patent expiration, other companies get the rights to produce low-cost generics.

COMPETITIVE INSIGHTS

The companies are eminently functioning in the APAC antidepressants drugs, devices, and therapies market are Pfizer, GlaxoSmithKline, Abbot Laboratories, Brainsway, Neuronetics, Mayo Clinic, F. Hoffmann-La Roche Ltd., H. Lundbeck AS, Eli Lilly and Company, Allergan PLC and Boehringer Ingelheim GmbH.


1. Research Scope
1.1. Study Goals 1.2. Scope Of The Market Study 1.3. Who Will Find This Report Useful? 1.4. Study And Forecasting Years
2. Research Methodology
2.1. Sources Of Data 2.1.1. Secondary Data 2.1.2. Primary Data 2.2. Top-down Approach 2.3. Bottom-up Approach 2.4. Data Triangulation
3. Executive Summary
3.1. Market Summary 3.2. Key Findings 3.2.1. Serotonin And Norepinephrine Reuptake Inhibitors (Snris) Is The Dominant Drug In Antidepressants Market3.2.2. Deep Brain Stimulator Is Expected To Grow Fast Among Other Devices Over The Forecast Period 3.2.3. Cognitive Behavior Therapy (Cbt) Is The Largest Contributor To The Antidepressants Therapies Market
4. Market Dynamics
4.1. Market Definition & Scope 4.2. Market Drivers 4.2.1. Rise In The Number Of Depression Patients 4.2.2. Increase In Aging Population 4.2.3. Rising Consciousness Of Depression As A Medical Disorder 4.2.4. Surge In Sales Of Antidepressants 4.3. Market Restraints 4.3.1. High Cost Of Depression Therapy 4.3.2. Patent Expiration Faced By The Companies 4.3.3. Delay In Product Launches 4.4. Market Opportunities 4.4.1. Huge Market Potential 4.4.2. More Preference For Personnel Therapy & Device Treatment 4.5. Market Challenges 4.5.1. Stiff Competition From The Generic Drugmakers
5. Market By Antidepressants Drugs
5.1. Serotonin And Norepinephrine Reuptake Inhibitors (Snris)5.2. Tricyclic Antidepressants (Tcas) 5.3. Monoamine Oxidase Inhibitors (Maois) 5.4. Atypical Antidepressants 5.5. Selective Serotonin Reuptake Inhibitors 5.6. Benzodiazepines 5.7. Anticonvulsants 5.8. Beta-blockers 5.9. Other Antidepressants Drugs
6. Market By Devices
6.1. Deep Brain Stimulators 6.2. Fisher Wallace Stimulators 6.3. Transcranial Magnetic Stimulator 6.4. Other Devices
7. Market By Therapies
7.1. Cognitive Behavior Therapy (Cbt) 7.2. Electroconvulsive Therapy (Ect) 7.3. Rational Emotive Behavior Therapy (Rebt) 7.4. Other Therapies
8. Key Analytics
8.1. Porter’s Five Force Model 8.1.1. Threat Of New Entrants 8.1.2. Threat Of Substitute 8.1.3. Bargaining Power Of Suppliers 8.1.4. Bargaining Power Of Buyers 8.1.5. Threat Of Competitive Rivalry 8.2. Opportunity Matrix 8.3. Vendor Landscape 8.4. Value Chain Analysis 8.4.1. For Drugs 8.4.2. For Devices 8.5. Key Buying Criteria
9. Geographical Analysis
9.1. Asia Pacific 9.1.1. India 9.1.2. China 9.1.3. Japan 9.1.4. South Korea 9.1.5. Australia 9.1.6. Rest Of Asia Pacific (Roapac)
10. Competitive Landscape
10.1. Market Share Analysis10.2. Company Profile 10.2.1. Abbot Laboratories 10.2.2. Allergan Plc 10.2.3. Boehringeringelheim Gmbh 10.2.4. Brainsway 10.2.5. Eli Lilly And Company 10.2.6. F. Hoffmann-la Roche Ltd. 10.2.7. Glaxosmithkline 10.2.8. H. Lundbeck As 10.2.9. Mayo Clinic 10.2.10. Neuronetics 10.2.11. Pfizer
List Of Tables
Table 1 Asia Pacific Antidepressants Drugs, Devices And Therapies Market, By Country, 2019-2027, (In $ Million) Table 2 Asia Pacific Antidepressants Drugs, Devices And Therapies Market, By Antidepressants Drugs, 2019-2027, (In $ Million) Table 3 Asia Pacific Antidepressants Drugs, Devices And Therapies Market, By Devices, 2019-2027, (In $ Million) Table 4 Asia Pacific Antidepressants Drugs, Devices And Therapies Market, By Therapies, 2019-2027, (In $ Million) Table 5 Opportunity Matrix Table 6 Vendor Landscape Table 7 Asia Pacific Antidepressants Drugs, Devices And Therapies Market, By Country, 2019-2027, (In $ Million)
List Of Figures
Figure 1 Asia Pacific Antidepressants Drugs, Devices And Therapies Market Share, By Drugs 2018 & 2027 (%) Figure 2 Snris Market, 2019 - 2027 (In $ Million) Figure 3 Deep Brain Stimulators Market, 2019-2027 (In $ Million) Figure 4 Cognitive Behavior Therapy (Cbt) Market (In $ Million) Figure 5 Asia Pacific Antidepressants Drugs, Devices And Therapies Market, By Cognitive Behavior Therapy (Cbt), 2019-2027, (In $ Million) Figure 6 Asia Pacific Antidepressants Drugs, Devices And Therapies Market, By Electroconvulsive Therapy (Ect), 2019-2027, (In $ Million) Figure 7 Asia Pacific Antidepressants Drugs, Devices And Therapies Market, By Rational Emotive Behavior Therapy (Rebt), 2019-2027, (In $ Million) Figure 8 Asia Pacific Antidepressants Drugs, Devices And Therapies Market, Other Therapies, 2019-2027, (In $ Million) Figure 9 Porter’s Five Force Model Figure 10 Value Chain Of Antidepressant Drugs Figure 11 Value Chain Analysis For Device Market Figure 12 Asia Pacific Antidepressants Drugs, Devices And Therapies Market, Regional Outlook, 2018 & 2027, (%) Figure 13 India Antidepressants Drugs, Devices And Therapies Market, 2019-2027 (In $ Million) Figure 14 China Antidepressants Drugs, Devices And Therapies Market, 2019-2027 (In $ Million) Figure 15 Japan Antidepressants Drugs, Devices And Therapies Market, 2019-2027 (In $ Million) Figure 16 South Korea Antidepressants Drugs, Devices And Therapies Market, 2019-2027 (In $ Million) Figure 17 Australia Antidepressants Drugs, Devices And Therapies Market, 2019-2027 (In $ Million) Figure 18 Rest Of Asia Pacific Antidepressants Drugs, Devices And Therapies Market, 2019-2027 (In $ Million)Figure 19 Market Share Of Antidepressants Drug Manufacturers (Percentage Of Sales), 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook